Funding Round
Neurophet raises $42M Series C for AI brain MRI analysis platform in South Korea and US
Korea JoongAng Daily3/23/2026·03/23/26🌐 Asia
Summary
Seoul-based Neurophet secured ₩56B ($42M) Series C from IMM Investment, Korea Development Bank, Bon Angels, and Samsung Ventures. The company's NEUROPHET AQUA brain MRI analysis platform has FDA 510(k) clearance for brain segmentation and is pursuing FDA clearance for Alzheimer's biomarker quantification. US commercial launch planned for Q2 2025.
Why it matters
Korean AI medical imaging companies are emerging as serious global competitors. Neurophet's FDA clearances and Samsung Ventures participation position them to compete directly with Siemens Healthineers and GE Healthcare in clinical AI neuroimaging.
#AI#AI Diagnostics#Alzheimers#Asia#Industry#Neuroimaging#Venture Capital
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trialAlready a member? Sign in